Data Insights

BNT-325 by Duality Biologics (Shanghai) for Epithelial Ovarian Cancer: Likelihood of Approval

BNT-325 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Epithelial Ovarian Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-325 in Epithelial Ovarian Cancer

Data Insights

BNT-325 by Duality Biologics (Shanghai) for Peritoneal Cancer: Likelihood of Approval

BNT-325 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Peritoneal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-325 in Peritoneal Cancer

Data Insights

BNT-325 by Duality Biologics (Shanghai) for Fallopian Tube Cancer: Likelihood of Approval

BNT-325 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Fallopian Tube Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-325 in Fallopian Tube Cancer

Data Insights

BNT-325 by BioNTech for Malignant Mesothelioma: Likelihood of Approval

BNT-325 is under clinical development by BioNTech and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II...

Data Insights

BNT-325 by BioNTech for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval

BNT-325 is under clinical development by BioNTech and currently in Phase II for Castration-Resistant Prostate Cancer (CRPC). According to GlobalData,...

Data Insights

BNT-325 by BioNTech for Non-Small Cell Lung Cancer: Likelihood of Approval

BNT-325 is under clinical development by BioNTech and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...